Comparative Pharmacology
Head-to-head clinical analysis: FENSOLVI KIT versus SUPPRELIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENSOLVI KIT versus SUPPRELIN LA.
FENSOLVI KIT vs SUPPRELIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate is a GnRH agonist that initially stimulates and then suppresses pituitary gonadotropin release by downregulating GnRH receptors, leading to decreased testosterone and estradiol levels.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
45 mg subcutaneously every 6 months.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
None Documented
None Documented
3-4 hours (terminal); clinical suppression of LH/FSH persists 4 weeks post-injection.
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Primarily renal (~80%) and biliary/fecal (~20%) as metabolites and unchanged drug.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Category C
Category C
GnRH Agonist
GnRH Agonist